Art

J-GLOBAL ID：201902246731639009   Reference number：19A2911954

Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells

ヒト白血病K562細胞におけるウォッシュアウト後のBCR-ABLチロシンキナーゼ阻害剤(TKI)の連続的細胞静止効果

Author (5)： Aoyama Tsuyoshi (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) ,  Shibayama Yoshihiko (Department of Drug Fomulation, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido) ,  Furukawa Tatsuhiko (Department of Molecular Oncology, Graduate School Medical and Dental Sciences, Kagoshima University) ,  Sugawara Mitsuru (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) ,  Takekuma Yoh (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 42  Issue： 11  Page： 1805-1813(J-STAGE)  Publication year： 2019 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： K562 cell ,...
Semi thesaurus term： BCR/ABL ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2911954&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (10)： tyrosine kinase inhibitor ,  cytostatic effect ,  multidrug resistance protein-1 ,  chronic myeloid leukemia ,  P-glycoprotein ,  tyrosine kinase inhibitor ,  cytostatic effect ,  multidrug resistance protein-1 ,  chronic myeloid leukemia ,  P-glycoprotein

JST classification (1)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (3)： Imatinib ,  Dasatinib ,  Nilotinib

Reference (34)：

• 1) Nowell PC. The minute chromosome (Ph1) in chronic granulocytic leukemia. Ann. Hematol., 8, 65-66 (1962).
• 2) Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293 (1973).
• 3) Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer, 5, 172-183 (2005).
• 4) Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev., 18, 459-471 (2007).
• 5) Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111, 4022-4028 (2008).

Terms in the title (7)： ヒト ,  白血病K562細胞 ,  ウォッシュアウト ,  BCR-ABL ,  チロシンキナーゼ阻害剤 ,  細胞 ,  静止